Evidence map›Paper›PMID 41127031›Full record

ReviewFrontiers in pain research (Lausanne, Switzerland)2025

The burden of acute pain in the U.S. in the wake of the opioid crisis.

James C Hackworth, John E Schneider, Maggie Do Valle, David Fam, Charles Argoff, Emanuela Offidani, Jim Potenziano

Abstract readReview
In one paragraph

Review in Frontiers in pain research (Lausanne, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James C HackworthTris Pharma, Monmouth Junction, NJ, United States.
John E SchneiderAvalon Health Economics, Morristown, NJ | Miami, FL, United States.
Maggie Do ValleAvalon Health Economics, Morristown, NJ | Miami, FL, United States.
David FamTris Pharma, Monmouth Junction, NJ, United States.
Charles ArgoffAlbany Medical College, Albany, NY, United States.
Emanuela OffidaniTris Pharma, Monmouth Junction, NJ, United States.
Jim PotenzianoTris Pharma, Monmouth Junction, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of acute pain has grown substantially over the past two decades, due primarily to more surgeries, an aging population, and the rapid growth in the prevalence of metabolic disease. Although opioids are often the only effective treatment for many types of acute pain, especially severe acute pain, their use, even over a short period of time, comes with substantial risks of dependence, misuse, and diversion. Moreover, a large fraction of the patients currently suffering from opioid use disorder and those dying from opioid overdoses had their first exposure as pain patients. Conversely, refraining from using opioids in cases where other treatment options are ineffective creates a different set of risks. This potential undertreatment of acute pain, especially severe acute pain, increases the risk of acute pain transitioning to chronic pain. The use of opioids to treat acute pain and the ineffective treatment of acute pain have important implications for population health and health care costs.

Indexed as

acute painchronification of painhealthcare costsopioid use disorder (OUD)pain managementundertreatment

Identifiers

PMID41127031
PMCPMC12537733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.